Association Between Kratom () Use and Metabolic Syndrome

Overview

Journal Heliyon

Specialty Social Sciences

Date 2022 May 26

PMID 35615431

Authors

Aroon La-Up

Paleeratana Wongrith

Wiraphon Chaichan

Apinun Aramrattana

Udomsak Saengow

Affiliations

Soon will be listed here.

Abstract

Background And Aims: There are evidence about effects of kratom () use on parameters related to metabolic syndrome (MetS). The present study aimed to determine the association between kratom use and MetS.

Methods: This study is a cross-sectional study of 581 subjects (kratom users and non-users) aged 18 and over from the Nam Phu sub-district, Surat Thani province, Thailand. The association was determined using multivariate logistic regression.

Results: MetS prevalence in kratom users and non-users was 11.9% (95% CI, 8.4-16.3%) and 21.6 % (95% CI, 17.1-26.8%), respectively. The use of kratom was associated with the lower odds of MetS (adjusted OR, 0.56; 95% CI, 0.33-0.96). Kratom use were associated with smaller waist circumference, lower triglycerides, and higher high-density lipoprotein.

Conclusions: The current study demonstrated a potential protective effect of kratom use against MetS.

Citing Articles

An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans.

Prevete E, Theunissen E, Kuypers K, Paci R, Reckweg J, Cavarra M Psychopharmacology (Berl). 2024; .

PMID: 39724441 DOI: 10.1007/s00213-024-06734-2.

Clinical Implications of Kratom () Use: a Literature Review.

Prevete E, Kuypers K, Theunissen E, Esposito G, Ramaekers J, Pasquini M Curr Addict Rep. 2023; 10(2):317-334.

PMID: 37266188 PMC: 10177737. DOI: 10.1007/s40429-023-00478-3.

References

Kruegel A, Gassaway M, Kapoor A, Varadi A, Majumdar S, Filizola M . Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc. 2016; 138(21):6754-64. PMC: 5189718. DOI: 10.1021/jacs.6b00360. View

La-Up A, Saengow U, Aramrattana A . High serum high-density lipoprotein and low serum triglycerides in Kratom users: A study of Kratom users in Thailand. Heliyon. 2021; 7(4):e06931. PMC: 8102425. DOI: 10.1016/j.heliyon.2021.e06931. View

Gordillo-Moscoso A, Ruiz E, Carnero M, Reguillo F, Rodriguez E, Tejerina T . Relationship between serum levels of triglycerides and vascular inflammation, measured as COX-2, in arteries from diabetic patients: a translational study. Lipids Health Dis. 2013; 12:62. PMC: 3667010. DOI: 10.1186/1476-511X-12-62. View

Saingam D, Assanangkornchai S, Geater A, Balthip Q . Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: a qualitative study. Int J Drug Policy. 2012; 24(4):351-8. DOI: 10.1016/j.drugpo.2012.09.004. View

Singh D, Muller C, Murugaiyah V, Hamid S, Vicknasingam B, Avery B . Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. J Ethnopharmacol. 2017; 214:197-206. DOI: 10.1016/j.jep.2017.12.017. View

Aekplakorn W, Chariyalertsak S, Kessomboon P, Sangthong R, Inthawong R, Putwatana P . Prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai National Health Examination Survey IV, 2009. Diabetes Care. 2011; 34(9):1980-5. PMC: 3161276. DOI: 10.2337/dc11-0099. View

Vicknasingam B, Narayanan S, Beng G, Mansor S . The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010; 21(4):283-8. DOI: 10.1016/j.drugpo.2009.12.003. View

Jang S, Jang B, Ko Y, Sasaki Y, Park J, Hwang E . Herbal Medicines for Treating Metabolic Syndrome: A Systematic Review of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2016; 2016:5936402. PMC: 4930818. DOI: 10.1155/2016/5936402. View

Kruegel A, Uprety R, Grinnell S, Langreck C, Pekarskaya E, Le Rouzic V . 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Cent Sci. 2019; 5(6):992-1001. PMC: 6598159. DOI: 10.1021/acscentsci.9b00141. View

10.

Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills A, Misra A . Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017; 17(1):101. PMC: 5251315. DOI: 10.1186/s12889-017-4041-1. View

11.

Prozialeck W, Avery B, Boyer E, Grundmann O, Henningfield J, Kruegel A . Kratom policy: The challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019; 70:70-77. PMC: 7881941. DOI: 10.1016/j.drugpo.2019.05.003. View

12.

Saklayen M . The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. PMC: 5866840. DOI: 10.1007/s11906-018-0812-z. View

13.

Leong Bin Abdullah M, Singh D . The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom ( Korth.): A Comprehensive Review. Front Pharmacol. 2021; 12:726003. PMC: 8504575. DOI: 10.3389/fphar.2021.726003. View

14.

Chittrakarn S, Sawangjaroen K, Prasettho S, Janchawee B, Keawpradub N . Inhibitory effects of kratom leaf extract (Mitragyna speciosa Korth.) on the rat gastrointestinal tract. J Ethnopharmacol. 2008; 116(1):173-8. DOI: 10.1016/j.jep.2007.11.032. View

15.

Jansen K, Prast C . Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol. 1988; 23(1):115-9. DOI: 10.1016/0378-8741(88)90121-3. View

16.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

17.

Liu X, Chen Y, Boucher N, Rothberg A . Prevalence and change of central obesity among US Asian adults: NHANES 2011-2014. BMC Public Health. 2017; 17(1):678. PMC: 6389198. DOI: 10.1186/s12889-017-4689-6. View

18.

Fan W, Philip S, Granowitz C, Toth P, Wong N . Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014. Cardiol Ther. 2020; 9(1):207-213. PMC: 7237595. DOI: 10.1007/s40119-020-00170-x. View

19.

Prozialeck W, Jivan J, Andurkar S . Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012; 112(12):792-9. View

20.

Parthasarathy S, Bin Azizi J, Ramanathan S, Ismail S, Sasidharan S, Said M . Evaluation of antioxidant and antibacterial activities of aqueous, methanolic and alkaloid extracts from Mitragyna speciosa (Rubiaceae family) leaves. Molecules. 2009; 14(10):3964-74. PMC: 6255380. DOI: 10.3390/molecules14103964. View